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Japanese encephalitis virus (JEV) infects a broad range of cell types in vitro, though little is known about the initial events
of JEV infection. In the present study, we found that highly sulfated glycosaminoglycans (GAGs) are involved in infection of
both neurovirulent (RP-9) and attenuated (RP-2ms) JEV strains. Competition experiments using highly sulfated GAGs, heparin
and dextran sulfate, demonstrated an inhibition of JEV’s attachment and subsequent infection of BHK-21 cells. Treatment of
target cells by a potent sulfation inhibitor, sodium chlorate, greatly reduced viral binding ability as well as infection,
suggesting a critical role of GAGs’ sulfation status on the cellular surface in JEV infection. This phenomenon was confirmed
by the manifestation of a distinct binding efficiency of JEV to the wild-type CHO cell line and its mutants with defects in GAG
biosynthesis. We also demonstrated the binding of JEV particles and virus envelope glycoprotein to immobilized heparin
beads. Furthermore, the addition of heparin suppressed the cytopathic effects induced by JEV infection in cultured cells. Our
results establish that the highly sulfated form of GAGs on cell surfaces plays a determining role in the early stage of in vitro
JEV infection. © 2001 Academic Press
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Japanese encephalitis virus (JEV) is a mosquito-borne
flavivirus responsible for acute encephalitis in humans.
Among the medically important flaviviruses, JEV infection
has the highest mortality rate, with more than 10,000
annual deaths worldwide, and remains as a major public
health problem in several parts of Asia (Burk and Leake,
1988; Vaughn and Hoke, 1992). The genome of the virus
is a single-stranded, positive-sense RNA of about 11 kb,
which contains a single open reading frame (ORF) en-
coding a polyprotein that is subsequently cleaved into a
number of structural and nonstructural proteins. The 59
one third of the ORF encodes three viral structural pro-
teins, namely, capsid (C), membrane (M), and envelope
(E), while the 39 two thirds encodes nonstructural pro-
teins designated NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5 (Chambers et al., 1990; Rice, 1996).
Virus binding to the host cell surface receptor(s) is the
first step in the virus replication cycle, which dictates the
tissue tropism and pathogenesis of many viruses. Similar
to most enveloped animal viruses, JEV is believed to
utilize receptor-mediated endocytosis for the initiation of
infection (Chambers et al., 1990). No known cellular mol-
ecule has thus far been identified as a receptor for JEV
infection, whereas the interacting counterpart on JEV
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206particles has been suggested to be glycoprotein E, be-
cause E, but not other virus structural proteins, is the
major target for neutralizing antibodies (Heinz, 1986; Ha-
segawa et al., 1992). Experimental data have demon-
strated that changes in the E protein can alter several
aspects of the biological properties of JEV. For example,
mutations in the E protein of JEV influence viral entry into
cultured cells and viral virulence in mice (Hasegawa et
al., 1992) and are responsible for the loss of viral neuro-
invasiveness in mice (Cecilia and Gould, 1991), as well
as for the molecular basis of virus attenuation (Aihara et
al., 1991; Ni et al., 1994, 1995; Sumiyoshi et al., 1995).
Many pathogenic microorganisms have the ability to
utilize surface glycoconjugates as cellular receptors for
attachment, which enables microbes to take their first
step toward establishing an infection (Rostand and Esko,
1997; Wadstrom and Ljungh, 1999). Proteoglycans are
widely expressed in different kinds of animal cells (Prydz
and Dalen, 2000). They can be found in intracellular
secretion granules, on the cell surface, and in associa-
tion with the extracellular matrix. Characteristically, pro-
teoglycans consist of a protein portion in conjunction
with one or more covalently attached glycosaminoglycan
(GAG) chains, which comprise many repeating disaccha-
ride units (Jackson et al., 1991; Kjellen and Lindahl, 1991).
There are two major types of GAG chains found in animal
cells: heparan sulfate (HS) and chondroitin sulfates. As
chains polymerize, GAG chains undergo various levels of
sulfation that result in the addition of sulfate groups to
different sugar moieties. Heparin, the most highly sul-
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207HEPARIN AND JEVfated GAG, is a close structural homologue of HS and is
primarily found in intracellular granules of mast cells.
Many enveloped and nonenveloped viruses utilize HS
and/or heparin to mediate attachment and infection to
target cells, including vaccinia virus (Chung et al., 1998),
herpesviruses (WuDunn and Spear, 1989; Lycke et al.,
1991; Shieh et al., 1992), human immunodeficiency virus
(Patel et al., 1993; Roderiquez et al., 1995; Mondor et al.,
998), dengue virus serotype 2 (DEN-2) (Chen et al.,
997), Sindbis virus (Byrnes and Griffin, 1998; Klimstra et
l., 1998), picornaviruses (Jackson et al., 1996), and pap-
llomavirus (Joyce et al., 1999), etc.
The natural life cycle of JEV involves complex relation-
hips among arthropods, vertebrate reservoirs, and hu-
ans, illustrating a broad host spectrum for JEV infection
Monath and Heinz, 1996). A wide variety of tissue culture
ells from different origins, e.g., monkey, hamster, por-
ine, chicken, and mosquito, can support productive
rowth of JEV. Early interactions between viruses and
ells appear to determine the susceptibility of target
ells to JEV infection (Kimura et al., 1994). Although they
ave not been confirmed as receptors, a 57-kDa protein
erived from BHK-21 cells (Chen et al., 1996b) and a
4-kDa molecule from Vero cells (Kimura et al., 1994)
ere demonstrated to bind to JEV particles. However, it
s not clear whether JEV is similar to the viruses listed
bove in its ability to utilize cellular proteoplycans for
iral attachment. Therefore, in the present study we used
wo plaque-purified JEV strains, which differ in virulence
nd plaque morphology (Chen et al., 1996b), to investi-
ate the role of cellular GAGs in JEV infection. Our results
emonstrate that regardless of the virus strain, the ad-
ition of highly sulfated heparin interferes with the viral
FIG. 1. The effects of glycosaminoglycans (GAGs) on JEV infection. B
100–200 PFU of JEV strain RP-9 (A) or RP-2ms (B) at 37°C for 1 h, and th
of plaque formation was calculated as 100 3 (the plaque numbers of G
dextran sulfate; H, heparin; HS, heparan sulfate; CS, chondroitin sul
independent experiments. The results of each treatment were compar
**P , 0.001.ttachment step, thus blocking plaque formation and the
ytopathic effects induced by JEV infection. We also
h
pound that JEV E protein can directly bind to heparin.
urthermore, the attenuated JEV strain with small-plaque
orphology (RP-2ms) appeared to bind immobilized hep-
rin more strongly than the virulent strain with large-
laque morphology (RP-9) in an in vitro binding assay.
he relevance and possible molecular mechanism of this
henomenon with respect to JEV pathogenesis are dis-
ussed.
RESULTS
nhibition of JEV plaque formation by GAGs
To investigate whether GAGs are involved in JEV in-
ection, soluble GAGs (including heparan sulfate and
hondroitin sulfate A), heparin (an analogue of highly
ulfated heparan sulfate), and dextran sulfate (an artifi-
ial, highly sulfated polysaccharide) were employed in
laque reduction assays. Two plaque-purified strains of
EV, a virulent RP-9 that forms large plaque and an
ttenuated RP-2ms that exhibits smaller plaque on
HK-21 cells (Chen et al., 1996b), were used in this study.
ince in vitro cultivation has been reported to select for
iruses with higher affinity to heparan sulfate (Sa-Car-
alho et al., 1997; Klimstra et al., 1998), we chose to use
the virus stocks of similar in vitro passage history (five or
six passages in BHK-21 and then one passage in C6/36
cells) for both RP-9 and RP-2ms throughout the study.
The results in Fig. 1A show that heparin (H) and dextran
sulfate (DS), both highly sulfated forms of GAGs, effec-
tively blocked the plaque formation of RP-9 on BHK-21
cells. In contrast, heparan sulfate (HS) or chondroitin
sulfate (CS) did not affect the plaque formation of RP-9,
even at a concentration as high as 10 mg/ml. On the other
ells were incubated with various concentrations of soluble GAGs and
s were washed and overlaid for plaque determination. The percentage
ated groups divided by the plaque numbers of untreated controls); DS,
The data shown here are the average and standard error of three
eir untreated control by Student’s t test, *P , 0.05, **P , 0.01, andHK-21 c
en cell
AG-tre
fate A.and, all GAGs except chondroitin sulfate inhibited the
laque formation of RP-2ms to certain extents, yet hep-
action, c
208 SU ET AL.arin and dextran sulfate still exhibited a greater inhibitory
effect than chondroitin sulfate or heparan sulfate (Fig.
1B). It seems from data in Fig. 1 that a low dose of
heparin (1 mg/ml) inhibited RP-9 more than RP-2ms on
plaque formation (P , 0.05 by Student’s t test), whereas
higher dose of heparin (10 mg/ml) appeared to block
RP-2ms to a greater extent than RP-9 (P , 0.05 by
Student’s t test). It remains unclear why heparin could
exhibit a dose-dependent inhibition of RP-2ms but not
RP-9. The finding that heparin has a stronger effect than
heparan sulfate on inhibiting JEV plaque formation is
similar to the finding from a previous study of dengue
virus (Chen et al., 1997). These observations suggest that
the sulfation level of GAGs might contribute to their
interference with JEV to form plaques on cultured cells.
Cell surface sulfation affected JEV infection
Chlorate is a competitive inhibitor of sulfation because
it competes for sulfate recognition by ATP sulfurylase,
the first enzyme in the sulfate assimilation pathway (Far-
ley et al., 1978). Addition of sodium chlorate has been
reported to reduce the sulfation levels of proteins and
FIG. 2. The effect of sodium chlorate on JEV infection. Percentages o
for 1 week in the presence or the absence of 6.25 mM sodium chlorate
with and without the addition of 0.8 mM sodium sulfate supplement. Th
to Fig. 1. (C) Immunofluorescent assay. BHK-21 cells treated with or wi
5) with and without supplement by 1 mM sodium sulfate. After O/N infe
Materials and Methods.heparan sulfate on cell surfaces (Baeuerle and Huttner,
1986; Safaiyan et al., 1999). To examine whether sulfationlevels affect JEV infection, sodium chlorate-treated
BHK-21 cells were examined using plaque reduction
assays. Compared to the untreated control, the plaque
formation ability of RP-9 or RP-2ms decreased to around
50% after sodium chlorate treatment, whereas supple-
menting sodium chlorate-treated cells with sodium sul-
fate greatly rescued JEV plaque formation (Figs. 2A and
2B). By immunofluorescent staining with anti-JEV NS1-
specific moAb (Chen et al., 1996a), a similar result was
found (Fig. 2C). Maintaining BHK-21 cells in medium
containing sodium chlorate (Fig. 2C, e) greatly reduced
the positive staining rate for JEV (RP-9) infection,
whereas supplement with sodium sulfate during infec-
tion (Fig. 2C, g) significantly reversed JEV infectivity back
to the normal level of controls (Fig. 2C, a and c). These
results strongly suggest that sulfation levels on the cell
surface of BHK-21 cells play an important role in JEV
infection.
Heparin inhibits JEV binding to a highly sulfated
cellular component(s)
An assay of virus binding to target cells (Chen et al.,
e formation by (A) RP-9 and (B) RP-2ms. BHK-21 cells were maintained
I medium containing 5% FBS. Plaque reduction assays were performed
entage of plaque formation was calculated as described in the legend
mM sodium chlorate for 1 week were infected with JEV (RP-9, m.o.i.,
ells were stained with anti-JEV NS1 Ab and DAPI, as described underf plaqu
in RPM
e perc
thout 101996b) was conducted to determine whether the plaque
reduction shown in Figs. 1 and 2 was due to direct
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209HEPARIN AND JEVinterference of heparin with viral attachment to target
cells. BHK-21 cells were first adsorbed by JEV particles in
the absence or the presence of heparin at 4°C for 1 h, a
condition that allows virus to bind to, but not penetrate
into, the target cells. After incubation, the bound viruses
were dissociated from the cells and quantitated by
plaque assay, as described under Materials and Meth-
ods. The results in Fig. 3A revealed that the amount of
RP-9 or RP-2ms binding to BHK-21 cells gradually de-
clined as the concentration of heparin was increased.
Heparin treatment appeared to influence the binding of
RP-2ms to the cell surface more than that of RP-9 (P ,
0.01 by two-way ANOVA) (Fig. 3A). In response to ;10
mg/ml of heparin, the lesser binding of RP-2ms to the cell
surface (Fig. 3A) might result in less plaque formation of
RP-2ms (Fig. 1). Treatment of cells with sodium chlorate
also diminished the amount of JEV adsorbed on cell
surfaces (Fig. 3B), indicating that the binding between
JEV and cells is sulfation dependent. These observations
suggest that heparin might interfere with JEV’s binding to
the highly sulfated, cellular component(s) on the host cell
surface. The difference between these two viruses in
their ability to bind heparin was further tested by an in
itro binding assay using heparin–Sepharose beads. As
hown in Fig. 3C, RP-2ms bound to heparin beads more
trongly than did RP-9 when comparing the ratios of
FIG. 3. Viral binding assay. (A) BHK-21 cells were incubated with JEV
RP-9 or RP-2ms (m.o.i., 1) in the presence of various concentrations of
heparin at 4°C for 1 h. The viruses bound on cell surfaces were
dissociated by passing the cells through a 27-gauge needle, and the
titers were then determined by plaque assays. (B) BHK-21 cells were
treated with different doses of sodium chlorate for 1 week, and the
resulting cells were used for binding assays as described in A. (C) The
in vitro binding efficiency of JEV to immobilized heparin. JEV RP-9 and
RP-2ms were tested for their ability to bind heparin–CL-6B as described
under Materials and Methods. The amount of JEV in each portion was
determined by plaque assay.nput and bound virus titers. The higher in vitro binding
fficiency of RP-2ms to heparin may partially explain why
a
(the interactions between RP-2ms and host cells are
somewhat more affected by heparin.
Mutants of the GAG synthesis pathway inhibit JEV
binding
To further investigate the requirement of heparin for
JEV binding, we used several CHO cell derivatives, each
with different defects in GAG synthesis, for JEV binding
tests. The mutant line pgsA-745 is deficient in xylosyl-
transferase and thus completely lacks GAG synthesis
(Esko et al., 1985). The mutant pgsD-677 is deficient in
heparan sulfate synthesis and overproduces chondroitin
sulfates instead (Lidholt et al., 1992). The mutant pgsE-
606 is defective in heparan sulfate N-sulfotransferase
and thus can only produce undersulfated forms of hepa-
ran sulfate proteoglycan (Bame and Esko, 1989). Char-
acteristically, all these mutants fail to synthesize highly
sulfated heparan sulfate. The amounts of JEV binding to
these cells were revealed by virus titration and immuno-
blotting assays, as described under Materials and Meth-
ods. As shown in Fig. 4A, both RP-9 and RP-2ms bound
to the wild-type CHO-K1 much more efficiently than to the
GAG mutant cells. The amount of E protein bound on the
target cell surface was further confirmed by Western
immunoblotting (Fig. 4B) and it also appears that wild-
type CHO-K1 cells could bind more JEV particles when
compared to their GAG mutants. These results, again,
FIG. 4. The binding of JEV on CHO-K1 and its proteoglycan mutant
cells. (A) Virus binding assay; 1.5 3 106 PFU of RP-9 or RP-2ms were
bound to 5 3 105 CHO-K1 or its GAG mutant pgsA-745, pgsD-677, and
gsE-606 cells (m.o.i., 3) at 4°C for 1 h. The amounts of virus bound to
he cells were dissociated and titrated as described in the legend to
ig. 3. The data shown here are the average and standard error of three
ndependent experiments. (B) After virus binding as described in A, the
ells were lysed, and the lysates were separated by 10% SDS–PAGE
nd then immunoblotted with anti-JEV E moAb (top) or anti-actin Ab
Chemicon International, Inc., CA) (bottom).
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210 SU ET AL.demonstrate an important role for the highly sulfated
forms of heparan sulfate in JEV binding to the target cells.
JEV particles and JEV’s envelope protein bind to
immobilized heparin in vitro
To determine how heparin affects JEV infection,
HK-21 cells were treated with heparin prior to and after
he virus adsorption step. We found that the ability of
laque formation did not significantly change when cells
ere pretreated with heparin before JEV adsorption (data
ot shown), suggesting that the target for heparin to
xert its inhibitory function is likely on the virus particles,
ot on the cell surface. This notion was supported by the
irect binding between JEV particles and immobilized
eparin beads and by the specific binding between hep-
rin beads and JEV E protein. In fact, virus particles of
oth RP-9 (data not shown) and RP-2ms (Fig. 5A, lane 1)
ound to heparin–CL-6B beads, while neither of them
ould bind to the control CL-6B beads (Fig. 5A, lane 5). In
ddition, the direct binding between JEV E proteins and
eparin was further investigated using in vitro synthe-
sized full-length E protein and the ectodomain of E,
JEN-80%, which possesses a deletion in the C-terminal
transmembrane domain of the E protein. We found that
both forms of the E protein could bind to heparin beads
(Fig. 5B, lanes 3 and 4), but not to the control CL-6B
beads (lanes 5 and 6). These results illustrate that JEV E
protein can actually participate in the binding between
virus particles and heparin molecules.
We next sought to determine whether antibodies spe-
cific for JEV E protein could interfere with the binding
between virus particles and heparin beads. Antibodies
tested included a neutralizing anti-E Ab (Fig. 5A, lanes 2
and 6), a nonneutralizing anti-E Ab (lanes 3 and 7), and a
prebleed serum (lanes 4 and 8) to serve as a control.
None of these antibodies could interfere with the binding
between RP-9 (data not shown) or RP-2ms (Fig. 5A, lanes
2–4) and heparin beads. It is likely that the interaction
sites between JEV and heparin are multiple since no
single monoclonal anti-E Ab tested could block the bind-
ing process.
Addition of heparin suppressed the cytopathic effects
(CPE) induced by JEV infection
To confirm that the presence of heparin could indeed
repress the CPE induced by JEV infection, we assessed
the extent of cellular damage by measuring the amounts
of LDH, a cytoplasmic enzyme, leaked into culture media
from infected cells. A wild-type JEV strain, NT109, origi-
nally isolated from infected mosquitoes (Chen et al.,
1996b), instead of the plaque-purified RP-9 or RP-2ms,
was used to further study the general effect of heparin on
JEV infection. As shown in Fig. 6A, the levels of LDH
release measured at day 4 postinfection were elevated
proportionally to the amount of JEV (NT109) used in theinfection, and moreover, the addition of heparin sup-
pressed lactate dehydrogenase (LDH) release in a dose-
dependent manner. Since heparin has been reported to
inhibit the infectivity of DEN-2, which is another member
of the flaviviruses (Chen et al., 1997), we also included
and compared the effect of heparin on infection with JEV
and DEN-2. In the presence of varying concentrations of
heparin, we determined the amount of virus capable of
causing a cytopathic infection; that is, we determined the
FIG. 5. In vitro binding assay of JEV particles and JEV envelope
protein. (A) JEV (RP-2ms) was incubated with heparin–CL-6B (H-CL-6B,
lanes 1–4) or the control CL-6B (lanes 5–8) Sepharose beads alone
(lanes 1 and 5) or in the presence of an anti-JEV neutralizing antibody
(lanes 2 and 6), an anti-JEV nonneutralizing antibody (lanes 3 and 7), or
a preimmune serum (lanes 4 and 8). The bound viruses were eluted by
sample buffer, separated by 12% SDS–PAGE, and then immunoblotted
with an anti-JEV-E-specific antibody. The positions of immunoglobin (Ig)
and E proteins are indicated by arrows. (B) The recombinant full-length
JEV E protein (JE) or the ectodomain (N-terminal 80% of E protein,
JEN-80%) were expressed by in vitro transcription and translation (TNT)
and labeled with [35S]methionine. The TNT lysates (lanes 1–2) were
incubated with heparin–CL-6B (H-CL-6B, lanes 3 and 4) or control
CL-6B (lanes 5 and 6) Sepharose beads, and the bound proteins were
eluted by sample buffer, separated by 12% SDS–PAGE, and then flu-
orographed. The sizes in kDa and the positions of the molecular weight
markers are shown in the right.tissue culture infection doses, TCIDs, for JEV and DEN-2.
Even though the basal level of TCID patterns was differ-
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211HEPARIN AND JEVent between the two viruses, it appeared that both JEV
and dengue viruses were equally sensitive to heparin
suppression (Fig. 6B). In the presence of heparin, both
viruses’ TCIDs needed to be increased to trigger the
same degree of CPE as that in the control (Fig. 6B).
Overall, our results demonstrate that, similar to DEN-2,
heparin can also block JEV infection.
DISCUSSION
In this report, plaque reduction assays (Fig. 1) and
inhibition of virus-induced CPE (Fig. 6) showed that hep-
arin, a highly sulfated form of GAG, could restrain infec-
FIG. 6. Heparin reduced the cytopathic effect induced by JEV infec-
tion. (A) LDH release. BHK-21 cells were infected with different
amounts of JEV (NT109), which had been incubated with different doses
of heparin for 10 min. After 30-min adsorption, cells were washed with
PBS three times and then incubated for 4 days. The culture superna-
tants were harvested for LDH assay. The data shown here are [the
experimental LDH release 2 the LDH release from the mock-infected
cells]. (B) Tissue culture infection doses (TCID) for JEV and DEN-2 in
the presence of different amounts of heparin. BHK-21 cells were in-
fected with serial dilutions of JEV (NT109) or DEN-2 (PL046) as de-
scribed in A. The degree of cytopathic effect was measured by the
release of LDH. The TCID for each concentration of heparin was
defined as the minimal amount of virus required to cause LDH release
(experimental-mock) greater than 0.15 OD.tion by either virulent or attenuated JEV strains in cul-
tured cells. Virus binding assays (Fig. 3) and experimentsinvolving sulfation inhibition of target cells (Fig. 2)
showed that the effect of heparin on JEV infection is
probably mediated through its interference with virus
binding to highly sulfated molecules on the cell surface.
Findings using CHO cell derivatives, each with different
defects in GAG biosynthesis (Fig. 4), further supported
the importance of highly sulfated HS on JEV binding. We
also found that the major component from JEV particles
interacting with highly sulfated HS is likely the structural
glycoprotein E (Fig. 5). These results illustrate that the
highly sulfated forms of GAGs are critically involved in
JEV infection in vitro, primarily at the early stage of the
virus life cycle, regardless of whether the virus strains
are neurovirulent.
Our data also suggested that the attenuated JEV strain
RP-2ms, which has small-plaque size, might have higher
binding capability to GAGs than the neurovirulent RP-9,
which has large-plaque size (Figs. 1 and 3). RP-9 and
RP-2ms were both derived from a Taiwanese isolate,
NT109, yet they differ in several biological aspects in
vitro and in vivo (Chen et al., 1996b; Lin et al., 1996).
Studies from foot-and-mouth disease virus (FMDV) (Sa-
Carvalho et al., 1997), Sindbis virus (Byrnes and Griffin,
2000), and Venezuelan equine encephalitis virus (VEE)
(Bernard et al., 2000) have established a correlation
etween heparin binding and viral attenuation. The
echanism for attenuation has been proposed to be due
o a rapid viral clearance in vivo through binding of the
irus to ubiquitous heparan sulfate. In infected mice,
irulent RP-9 exhibits higher serum viremia and attenu-
ted RP-2ms mainly targets to liver (Chen et al., 1996b).
he results from the present study suggest that RP-2ms
ight be wiped out from the circulation through binding
o heparan sulfate and that the liver tropism of RP-2ms is
ikely an outcome of liver tissue containing large
mounts of highly sulfated HS (Lyon et al., 1994). Thus,
JEV appears to join a growing list of viruses whose
binding ability to HS/heparin inversely correlates to dis-
ease severity, which may, at least in part, explain the
molecular basis of viral pathogenesis.
For most viruses, the structural protein(s) appears to
be the major component to bind to HS/heparin. Linear
heparin binding domains (HBD) that often contain a clus-
ter of positively charged amino acids have been identi-
fied for several viruses (Flynn and Ryan, 1995; Feldman
et al., 1999). In the present study, we found that to initiate
virus infection, JEV appears to use its major structural
glycoprotein E to bind to highly sulfated HS on the cell
surface (Fig. 5). Proteins that possess binding affinity for
GAGs depend largely on electrostatic interaction among
positively charged Arg and Lys in side chains with neg-
atively charged sulfate moieties (Fromm et al., 1995). Two
putative GAG binding motifs have been reported in the E
protein of DEN-2, in residues 284–310 and 386–411
(Chen et al., 1997). The putative GAG binding regions
with highly positive charges are also found in JEV E
po
t
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212 SU ET AL.protein in residues 286–312 and 391–416, where the
nucleotide sequences are identical in these two regions
for RP-9 and RP-2ms (data not shown). Conceivably, JEV
E protein is capable of exploiting these two GAG binding
regions to bind to sulfated HS in a manner similar to that
suggested for DEN-2 (Chen et al., 1997). We suspect that
additional GAG binding sites might be present in the
structural protein of attenuated JEV strains, such as RP-
2ms. The mutation in residue 138 of the E protein has
been found in the pair of RP-9 and RP-2ms (Glu in RP-9
and Lys in RP-2ms) (Chen et al., 1996b), as well as in
other JEV attenuated mutants (Sumiyoshi et al., 1995). An
alteration to positively charged Lys might allow RP-2ms
to bind to HS/heparin more strongly than RP-9. These
observations are reminiscent of the glycoprotein E2 of
Sindbis virus (Klimstra et al., 1998; Byrnes and Griffin,
2000) and VEE (Bernard et al., 2000), where changes to
positively charged amino acids resulted in stronger bind-
ing to heparin and the formation of smaller plaque mor-
phology. However, the exact role of these positive-
charged amino acid changes in the JEV phenotype re-
mains to be further studied using infectious cDNA
clones.
HS binding has been implied to be a phenotype se-
lected during cell culture for several viruses. The virulent
parental FMDV (Sa-Carvalho et al., 1997), VEE (Bernard
et al., 2000), and Sindbis virus (Klimstra et al., 1998) have
been shown to be low-HS binding and have been sug-
gested to use a receptor(s) other than HS in nature. We
previously observed that a cellular protein of 57 kDa
bound to RP-9 but not to RP-2ms (Chen et al., 1996b),
suggesting that in addition to heparin, a virulent JEV
strain with large-plaque morphology may bind to another
critical molecule(s) on host cells at the early stage of
infection. However, different from the viruses listed
above, our results reveal that infection by the virulent JEV
strain (RP-9) of BHK-21 cells was still, more or less,
affected by heparin treatment (Figs. 1A and 3A). Since
the virus stocks of RP-9 and RP-2ms used here were
cultured in BHK-21 cells for five or six passages after
plaque purification, the HS binding phenotype for both
strains might actually reflect the culture adaptation.
Whether passages of RP-2ms in mouse brain can select
out low-HS binding JEV variants needs to be further
studied. Moreover, as the mosquito and its derived cul-
ture cells are often used for JEV amplification, it will be of
interest to investigate whether HS is also involved in
arthropod hosts for JEV infection and whether virus pas-
sages in mosquito cells can as well select out high-HS
binding variants. To address this issue thoroughly, one
needs to utilize JEV isolates with no or limited in vitro
assages in future experiments.
In conclusion, we found that the highly sulfated forms
f GAGs on target cell surfaces are critically involved in
he early stage of JEV infection, regardless of virus viru-
ence or plaque morphology. Glycoprotein E of JEV is themajor binding partner interacting with highly sulfated HS
molecules, and mutations in the putative GAG binding
domains in JEV structural protein likely determine virus
virulence. Thus, our results may provide a molecular
explanation for JEV pathogenesis.
MATERIALS AND METHODS
Chemicals
Heparin, dextran sulfate, heparan sulfate, chondroitin
sulfate A, and sodium chlorate were purchased from
Sigma. Heparin-conjugated CL-6B and control CL-6B
Sepharose beads were purchased from Pharmacia.
Cells
BHK-21 (baby hamster kidney) and CHO-K1 (Chinese
hamster ovary) and its proteoglycan mutant cells were
used in this study. CHO-K1 mutant cells, including pgsA-
745, pgsE-606, and pgsD-677, were purchased from
ATCC. Cells were maintained in RPMI 1640 or Ham’s
F12K medium supplemented with 5 or 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 100 mg/ml of streptomy-
cin, and 100 IU/ml of penicillin.
Viruses
Plaque-purified JEV strains RP-9 and RP-2ms and their
parental strain NT109 isolated from infected mosquitoes,
Cx. tritaeniorhynchus (Chen et al., 1996b), were used in
this study. Throughout this study, RP-9 and RP-2ms vi-
ruses of passage 5 or 6 in BHK-21 cells then amplified
once in C6/36 cells were used. The passage history of
NT109 was not recorded. JEV infection was conducted as
previously described (Lin et al., 1997). Briefly, the adsorp-
tion of JEV was performed with serum-free RPMI medium
at 37°C for 1 h. Virus-infected cells were incubated in
RPMI or Ham’s F12K medium containing 2 or 5% FBS.
Virus titers were determined by a plaque assay on
BHK-21 cells as previously described (Lin et al., 1997). A
Taiwanese local strain of DEN-2 (PL046) isolated from a
dengue fever patient (Lin et al., 1998b) was also used in
this study.
Plaque reduction assay
BHK-21 cells in six-well plates were treated with vari-
ous concentrations (duplicates for 0, 1, and 10 mg/ml
groups) of soluble GAGs and 100–200 plaque-forming
units (PFU) of viruses at 37 or 4°C as indicated for 1 h.
Cells were washed three times with serum-free RPMI
medium, overlaid with RPMI medium with 2% FBS and 1%
agarose (SeaPlaque, FMC BioProducts), and incubated
at 37°C for 4 days for plaque formation. The percentage
of plaque formation was calculated as 100 3 (the plaque
number of the drug treated group/the plaque number of
the control group from the same plate).
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infection
Sulfation in BHK-21 cells was inhibited by sodium
chlorate as previously described (Chen et al., 1997) with
some modifications. BHK-21 cells were maintained for 1
week in RPMI medium with 5% FBS containing different
amounts of sodium chlorate. Plaque reduction assays
were performed with cells treated with 6.25 mM sodium
chlorate in the presence or the absence of 0.8 mM
sodium sulfate supplement. For indirect immunofluores-
cent assays, BHK-21 cells were treated with or without 10
mM sodium chlorate in the presence or the absence of 1
mM sodium sulfate supplement. For virus binding as-
says, BHK-21 cells were treated with sodium chlorate at
a range from 0 to 25 mM.
Indirect immunofluorescence assays
Cells were fixed and permeabilized with acetone–
ethanol (1:1) at room temperature for 5 min. After block-
ing with 10% skim milk in PBS for 1 h, anti-JEV NS1
monoclonal antibody (Chen et al., 1996a) and fluorescein
isothiocyanate (FITC)-conjugated goat anti-mouse IgG
were used as primary and secondary antibodies, respec-
tively. Cellular nuclei were stained with DAPI in 0.9%
sodium chloride at room temperature for 5 min.
Viral binding assay
Viral binding assays were conducted as previously
described (Chen et al., 1996b). Briefly, BHK-21 cells were
incubated with JEV RP-9 or RP-2ms (m.o.i., 1) in the
presence of various concentrations of heparin at 4°C for
1 h. Cells were washed three times with cold PBS buffer
containing 1% bovine serum albumin and 0.1% Tween 20.
The viruses bound on cell surfaces were then dissoci-
ated by passing the cells through a 27-gauge needle,
and the titers were determined by plaque assays. The
amount of E protein bound on the cell surface was also
revealed by Western blotting with anti-JEV E Ab as pre-
viously described (Lin et al., 1997).
In vitro viruses and heparin–bead binding assay
The binding affinity of JEV to heparin was tested by an
in vitro heparin–bead binding assay as previously de-
scribed (Byrnes and Griffin, 1998) with some modifica-
tions. Heparin–CL-6B (H-CL-6B) Sepharose beads were
washed five times with PBS buffer. About 70 ml of beads
was mixed with viral supernatant (1 3 106 PFU of RP-2ms
or RP-9) in PBS and incubated on a rotator at 4°C. After
1 h, the unbound viral supernatants were collected. The
beads were then washed with 20 vol (667 ml three times)
f cold PBS buffer. Viral particles were eluted with 250 ml
of PBS buffer containing 400 mM NaCl at 4°C for 10 min.
Finally, the input, unbound, and bound viral titers were
determined by plaque assay. The titers for the bound
l
dviruses were determined on a 100-fold-diluted aliquot
due to the high salt condition.
In vitro viral proteins and heparin–bead binding assay
Heparin–CL-6B and CL-6B beads were washed three
times with PBS buffer. Aliquots of 100 ml of the beads
ere blocked with 1% of BSA in PBS for 1 h at 4°C.
reimmune mouse serum or anti-JEV E neutralizing or
onneutralizing moAb (Chen et al., 1996b) was added at
100-fold dilution and incubated for another 1 h. Two
undred microliters of viral supernatant was added into
ach tube and incubated on a rotator at 4°C for 1 h. After
he incubation, the beads were washed three times with
0 vol of cold PBS buffer. Viral particles were then eluted
ith 50 ml of sample buffer (2% SDS, 50 mM Tris–HCl, pH
.8, 0.1% bromophenol blue, 10% glycerol) without b-mer-
aptoethanol at room temperature for 30 min. The eluted
iruses were separated by 10% SDS–PAGE and analyzed
y Western blotting with anti-JEV E Ab as previously
escribed (Lin et al., 1997).
In vitro transcription and translation
Plasmids pJE and pJEN-80%, which are expression vector
pcDNA3 (Invitrogen) containing a 15-amino-acid signal
peptide from the C-terminus of M plus the full-length (nt
933–2477), or around the N-terminal 80% of E (nt 933–
2174) protein, respectively, were generated by RT–PCR
from RP-9 as previously described (Lin et al., 1998a).
Plasmid DNA was amplified in Escherichia coli DH5a
and isolated using a miniprep kit from Viogene. For
production of viral proteins, 1 mg of DNA was used in in
vitro transcription and translation (TNT T7 Quick Coupled
Rabbit Reticulocyte System, Promega) and labeled with
35S-Pro-mix (Amersham). The lysates (5 ml) were taken to
ind with 100 ml of CL-6B or Heparin–CL-6B beads at
4°C for 1 h. The beads were then washed with 20 vol of
PBS buffer. Finally, the bound proteins were eluted with
50 ml of sample buffer, separated by a 12% SDS–PAGE,
and fluorographed.
LDH assay
Cell viability was assessed by the release of cytoplas-
mic enzyme LDH using a commercial kit (Cytotoxicity
Detection Kit, Boehringer Mannheim) following the man-
ufacturer’s instructions. Briefly, the culture supernatants
from cell samples were clarified by centrifugation, mixed
with reaction mixture (diaphorase/NADH1, tetrazolium
alt INT/sodium lactate), incubated at RT for about 30
in, and then read by an ELISA reader at 490 nm (Mi-
roplate reader, Molecular Devices). LDH release is
hown as (the experimental reading 2 the reading of
ock-infected control). The TCID was determined as theowest virus titer able to cause a cytopathic infection
efined by an LDH release greater than 0.15 OD.
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